BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23852840)

  • 1. Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome.
    Emami Razavi A; Basati G; Varshosaz J; Abdi S
    Acta Med Iran; 2013 Jul; 51(6):365-71. PubMed ID: 23852840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
    Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
    Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain.
    Granér M; Tikkanen E; Rimpilä O; Tikkanen H; Ripatti S; Lokki ML; Nieminen MS; Taskinen MR; Sinisalo J
    Ann Med; 2013 Jun; 45(4):322-7. PubMed ID: 23651064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease.
    Yunoki K; Naruko T; Inaba M; Inoue T; Nakagawa M; Sugioka K; Ohsawa M; Iwasa Y; Komatsu R; Itoh A; Haze K; Yoshiyama M; Becker AE; Ueda M
    Atherosclerosis; 2013 Dec; 231(2):308-14. PubMed ID: 24267244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients.
    Bounafaa A; Berrougui H; Ikhlef S; Essamadi A; Nasser B; Bennis A; Yamoul N; Ghalim N; Khalil A
    Clin Biochem; 2014 Dec; 47(18):318-25. PubMed ID: 25218815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?
    Variji A; Shokri Y; Fallahpour S; Zargari M; Bagheri B; Abediankenari S; Alizadeh A; Mahrooz A
    Atherosclerosis; 2019 Jan; 280():7-13. PubMed ID: 30448568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients.
    Roman RM; Camargo PV; Borges FK; Rossini AP; Polanczyk CA
    Coron Artery Dis; 2010 May; 21(3):129-36. PubMed ID: 20305551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein composition and paraoxonase activity in Type I diabetes.
    Valabhji J; McColl AJ; Schachter M; Dhanjil S; Richmond W; Elkeles RS
    Clin Sci (Lond); 2001 Dec; 101(6):659-70. PubMed ID: 11724654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex.
    Huang Y; Wu Z; Riwanto M; Gao S; Levison BS; Gu X; Fu X; Wagner MA; Besler C; Gerstenecker G; Zhang R; Li XM; DiDonato AJ; Gogonea V; Tang WH; Smith JD; Plow EF; Fox PL; Shih DM; Lusis AJ; Fisher EA; DiDonato JA; Landmesser U; Hazen SL
    J Clin Invest; 2013 Sep; 123(9):3815-28. PubMed ID: 23908111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects.
    Vekic J; Kotur-Stevuljevic J; Jelic-Ivanovic Z; Spasic S; Spasojevic-Kalimanovska V; Topic A; Zeljkovic A; Stefanovic A; Zunic G
    Eur J Clin Invest; 2007 Sep; 37(9):715-23. PubMed ID: 17696961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the serum myeloperoxidase/high-density lipoprotein particle ratio and incident cardiovascular events in a multi-ethnic population: Observations from the Dallas Heart Study.
    Khine HW; Teiber JF; Haley RW; Khera A; Ayers CR; Rohatgi A
    Atherosclerosis; 2017 Aug; 263():156-162. PubMed ID: 28645072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myeloperoxidase in the plasma of patients with acute coronary syndrome].
    Ouyang M; Yang K; Zhang MX; Jiang WH; Cao Y; Wang JG; Gao YD
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Dec; 31(6):901-5. PubMed ID: 17213593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity.
    Huang J; Yancey PG; Tao H; Borja MS; Smith LE; Kon V; Davies SS; Linton MF
    Nutrients; 2020 Jun; 12(7):. PubMed ID: 32629758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
    Kimak E; Zięba B; Duma D; Solski J
    Lipids Health Dis; 2018 Apr; 17(1):71. PubMed ID: 29618370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients.
    Carnuta MG; Stancu CS; Toma L; Sanda GM; Niculescu LS; Deleanu M; Popescu AC; Popescu MR; Vlad A; Dimulescu DR; Simionescu M; Sima AV
    Sci Rep; 2017 Aug; 7(1):7295. PubMed ID: 28779156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.
    Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Schömig A; Kastrati A
    Eur J Clin Invest; 2008 Feb; 38(2):90-6. PubMed ID: 18226042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients.
    Jornayvaz FR; Brulhart-Meynet MC; James RW
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):613-9. PubMed ID: 19201174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity.
    Aggarwal G; May-Zhang LS; Yermalitsky V; Dikalov S; Voynov MA; Amarnath V; Kon V; Linton MF; Vickers KC; Davies SS
    J Biol Chem; 2021 Sep; 297(3):101019. PubMed ID: 34331945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease.
    Patel PJ; Khera AV; Jafri K; Wilensky RL; Rader DJ
    J Am Coll Cardiol; 2011 Nov; 58(20):2068-75. PubMed ID: 22051328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus.
    Ali EM; Shehata HH; Ali-Labib R; Esmail Zahra LM
    Clin Biochem; 2009 Sep; 42(13-14):1394-400. PubMed ID: 19538950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.